



LASA SUPERGENERICS LIMITED

Corporate Office : Office No . 705, Minerva Estate, Asha Nagar A Wing, O2 Commercial Tower,
Mulund (West) , Mumbai- 400 080
Email : info@lasalabs.com • Website : www.lasalabs.com

Ref. No.: LASA/SE/20-21/32

Monday, October 26 2020

To, Corporate Services Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001. BSE CODE –540702	To, Corporate Services Department National Stock Exchange of India Limited “Exchange Plaza”, Plot No. C/1, G Block Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051. NSE CODE: LASA
---	---

Dear Sir/Madam,

Sub. : **Outcome of Board Meeting held today i.e. October 26, 2020**

Pursuant to Regulation 29 and 30 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today through video conferencing which was commenced at 11.30 a.m. and concluded at 01:30 p.m. have considered, approved and took on record the Unaudited Financial Results for the quarter and Half year ended September 30 2020.

A copy of the statement of Unaudited Financial Results, Cash Flow statement along with Limited Review Report submitted by the Statutory Auditors of the Company is attached herewith.

The above information is also available on the company's website at www.lasalabs.com. and on the website of the stock Exchange at www.bseindia.com. and www.nseindia.com.

Please take the above on your records.

**THANKING YOU
YOURS SINCERELY
FOR LASA SUPERGENERICS LIMITED**



**NIDHI KULSHRESHTHA
COMPANY SECRETARY AND COMPLIANCE OFFICER**

Statement of Unaudited Financial Results for Quarter ended 30th Sep, 2020

(Rs. In Lakhs)

Particulars	Quarter ended			Half Year Ended		Year ended
	30.09.2020 (Unaudited)	30.06.2020 (Unaudited)	30.09.2019 (Unaudited)	30.09.2020 (Unaudited)	30.09.2019 (Unaudited)	31.03.2020 (Audited)
1. INCOME						
a. Revenue from Operations	5,469.09	5,459.97	4,041.19	10,929.06	7,939.59	16,727.12
b. Other Income	0.32	3.45	4.10	3.77	13.27	23.15
Total Income	5,469.41	5,463.42	4,045.29	10,932.83	7,952.87	16,750.27
2. Expenses						
a. Cost of Materials consumed	3,009.52	2,713.72	1,917.67	5,723.25	4,226.17	8,651.33
b. Cost of Traded Goods	-	-	-	-	49.41	49.41
c. Change in Inventories of Finished Goods, Work-in-Progress and Stock in trade	51.16	563.45	481.18	614.60	781.06	764.51
d. Employee benefits expenses	328.63	302.42	349.08	631.05	648.71	1,341.60
e. Finance costs	19.11	125.83	198.84	144.93	412.86	810.43
f. Depreciation & amortizations expenses	406.66	372.62	432.20	779.27	858.43	1,733.90
g. Other Expenses	799.98	662.50	542.49	1,462.49	980.34	2,925.49
Total Expenses (a to g)	4,615.06	4,740.53	3,921.46	9,355.59	7,956.98	16,276.66
Exceptional Items	-	-	-	-	-	-
3. Profit / (Loss) before tax (1-2)	854.35	722.89	123.83	1,577.24	(4.11)	473.60
4. Tax expense						
Current Tax	-	-	-	-	-	90.79
Deferred Tax	149.25	276.37	169.03	425.61	148.70	(16.77)
Short / Excess income tax provision for earlier years	-	(90.79)	-	(90.79)	-	36.75
5. Net Profit / (Loss) after tax (3-4)	705.10	537.32	(45.20)	1,242.42	(152.81)	362.83
6. Other Comprehensive Income						
Items that will not be reclassified into Profit or Loss						
- Remeasurement of Defined Benefit Plans (Net of tax)	-	-	-	-	-	3.94
7. Total Comprehensive Income for the year (after tax) (5+6)	705.10	537.32	(45.20)	1,242.42	(152.81)	366.77
8. Paid-up Equity Share Capital (Face Value of Re. 10/- each)	4,067.27	4,067.27	2,286.44	4,067.27	2,286.44	4,067.27
9. Other Equity excluding Revaluation reserve as per Balance Sheet				11,321.69	8,090.52	10,079.28
10. Earnings per Equity Share (of Rs. 10/- each)						
(a) Basic	1.73	1.32	(0.20)	3.05	(0.67)	1.26
(b) Diluted	1.73	1.32	(0.20)	3.05	(0.67)	1.26

Notes :

1) The Above Financial Results were reviewed by the audit committee of the board on **26th October, 2020** and approved by the Board of Directors of the company at their meeting held on same date. The Statutory auditors have expressed on unmodified opinion. The auditors report has been filed with stock exchange and is available on the company's website. The Financial results have been prepared in accordance with Ind AS notified under the Companies (Accounting Standards) Rule, 2015.

2) The Company has single business segment i.e. Active Pharmaceutical Ingredients (API), therefore, in the context of Ind As 108, disclosure of segment information is not applicable.

3) The Company continues to monitor the impact of Covid-19 on its business, including its impact on customers, supply-chain, employees and logistics. Due care has been exercised, in concluding on significant accounting judgements and estimates, including in relation to recoverability of receivables, assessment of impairment of goodwill and intangibles, investments and inventory, based on the information available to date, while preparing the Company's financial results as of and for the period ended September 30, 2020. The Company has adopted measures to curb the spread of infection in order to protect the health of our employees and ensure business continuity with minimal disruption.

4) Figures of previous period have been re-grouped / reclassified wherever necessary, to confirm to this period's classification.



By order of the Board of Directors
For Lasasupergenerics Limited

Omkar Herlekar
Chairman & Managing Director
(DIN No. 01587154)

(Rs. In Lakhs)

Particulars	As at 30.09.2020	As at 30.09.2019	As at 31 March 2020
ASSETS			
Non-current assets			
Property, Plant and Equipment	13,847.96	14,836.85	14,595.67
Capital Work in Progress	-	695.79	-
Intangible assets	593.31	623.28	623.28
Intangible assets under development	-	25.10	-
Financial Assets			
Non Current Investments	-	-	-
Loans	63.53	74.40	75.15
Deffered Tax Assets	(108.21)	153.32	317.41
	14,396.59	16,408.74	15,611.51
Current assets			
Inventories	1,863.37	2,291.69	2,630.48
<u>Financial Assets</u>			
Trade receivables	1,470.65	2,407.04	2,064.83
Cash and cash equivalents	137.68	63.63	256.84
Bank balances other than cash & cash equivalents	18.67	138.19	349.37
Loans	5.00	5.00	5.00
Other current assets	2,233.20	2,343.09	2,280.82
	5,728.57	7,248.65	7,587.35
	20,125.16	23,657.39	23,198.85
EQUITY AND LIABILITIES			
EQUITY			
Equity Share capital	4,067.27	2,286.44	4,067.27
Other Equity	11,321.69	8,090.52	10,079.28
	15,388.96	10,376.96	14,146.55
LIABILITIES			
Non-current liabilities			
<u>Financial Liabilities</u>			
Non Current Borrowings	727.00	3,914.60	1,414.24
Provisions	54.77	42.99	46.17
Deferred Tax Liabilities	-	-	-
	781.77	3,957.59	1,460.41
<u>Current liabilities</u>			
<u>Financial Liabilities</u>			
Current Borrowings	-	2,294.67	2,033.78
Trade payables	1,772.69	3,867.09	3,373.09
Other financial liabilities	1,424.92	1,806.92	1,393.15
Other current liabilities	158.81	868.74	295.33
Provisions	598.00	485.43	405.75
Current tax liabilities (net)	-	-	90.79
	3,954.42	9,322.85	7,591.89
	20,125.16	23,657.39	23,198.85

For Thanawala & Co.
Chartered Accountants
Firm Registration No.: 110948W

For Lasa Supergenerics Limited

SD/-
CA Vijay Thanawala
(Proprietor)
M.No.: 15632

Omkar Hedlekar
(Director)
DIN:01587154



Place : Mumbai
Date : 26th October, 2020

LASA SUPERGENERICS LIMITED
CIN: L24233MH2016PLC274202
Statement of Cash flows for the year ended Sep 30, 2020

(Rs. In Lakhs)

Particulars	Half year ended 30 Sept 2020	Half Year ended 30 Sep 2019	Year ended 31 March 2020
A. CASH FLOW FROM OPERATING ACTIVITIES			
Net (loss) / profit before tax	1,577.24	(4.11)	473.60
Adjustments for			
Depreciation and Amortisation Expense	779.27	858.43	1,733.90
Finance Costs	144.93	412.86	810.43
Interest income	3.13	(13.27)	(23.15)
Remeasurement of employee defined benefit obligation	-	-	5.33
Provision for doubtful debts and advances (net)	-	-	-
Operating profit before working capital changes	2,504.58	1,253.91	3,000.12
Working capital adjustments :-			
(Increase) / Decrease in Trade and Other Receivables	594.18	480.90	823.10
(Increase) / Decrease in Inventories	767.11	868.29	529.50
(Increase) / Decrease in Loans	11.62	(0.75)	(1.50)
(Increase) / Decrease in Other Current Assets	47.63	(80.81)	(18.53)
Increase / (Decrease) in Trade and Other Payables	(1,600.40)	(2,100.35)	(2,594.35)
Increase / (Decrease) in Provisions	200.85	243.56	167.06
Increase / (Decrease) in Other Financial Liabilities	31.77	219.91	(193.87)
Increase / (Decrease) in Other Current Liabilities	(136.52)	260.87	(312.54)
Cash generated from / (used In) operations	2,420.81	1,145.53	1,399.01
Direct taxes paid (Net of Refunds)	0.00	-	(36.75)
Net cash (used in) / from generated from operating activities	2,420.81	1,145.53	1,362.25
B. CASH FLOW FROM INVESTING ACTIVITIES			
Purchase of property, plant & equipment and intangible assets (including capital work-in-progress and capital advances)	(1.59)	(149.32)	(62.71)
Net (investments in)/ proceeds from bank deposits (having original maturity of more than three months)	330.70	88.22	(122.95)
Interest received	(3.13)	13.27	23.15
Net cash (used in) / generated from investing activities	325.97	(47.83)	(162.52)
C. CASH FLOW FROM FINANCING ACTIVITIES			
Proceeds from Issue of Share Capital (Considered as deemed inflow)	-	-	1,780.83
Proceeds from Capital Reserve	-	-	1,469.18
Interest paid	(144.93)	(412.86)	(810.43)
Proceeds from long-term borrowings (net)	(687.24)	(657.65)	(3,158.01)
Proceeds from short-term borrowings (net)	(2,033.78)	(5.65)	(266.54)
Redemption of investment	-	-	-
Net cash (used in) / from financing activities	(2,865.95)	(1,076.16)	(984.98)
Net decrease in cash and cash equivalents (A+B+C)	(119.16)	21.55	214.76
Cash and cash equivalents at the beginning of the year	256.84	42.08	42.08
Cash and cash equivalents at the end of the year	137.68	63.63	256.84
Components of cash and cash equivalents considered only for the purpose of cash flow statement			
In bank current accounts in Indian rupees	97.54	58.06	200.89
Cash on hand	40.14	5.57	55.95
	137.68	63.63	256.84

For Thanawala & Co.
Chartered Accountants
Firm Registration No.: 110948W

For Lasa Supergenerics Limited

sd/-
CA Vijay Thanawala
(Proprietor)
M.No.: 15632

Omkar Henekar
Director
DIN:01587154



Place : Mumbai
Date : 26th October, 2020



Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors
LASA SUPERGENERICS LIMITED

1. We have reviewed the accompanying statement of unaudited financial results of LASA SUPERGENERICS LIMITED (the "Company") for the quarter ended September 30, 2020 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules Issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Thanawala & Company
Chartered Accountants
Firm Reg. No.: 110948W

VIJAY
KANTILAL
THANAWALA
THANAWALA
Digitally signed by
VIJAY KANTILAL
THANAWALA
Date: 2020.10.26
12:19:14 +05'30'

CA Vijay Thanawala
Proprietor
Membership No.: 015632
UDIN: 20015632AAAACS7388

Place: Mumbai
Date: 26th October 2020